Your cart is currently empty!.
You may check out all the available products and buy some in the shop.
Continue Shopping
Zoetis Inc (ZTS) (Q4FY24) – Sustaining growth through innovation and market leadership
$232.00
Zoetis reported a strong financial year with $9.3 billion in revenue, representing an 8% increase on a reported basis and an 11% operational growth.
Description
Description
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
Revenue from the US has increased by 4% in Q4FY24 to $1.25bn from $1.211bn in the same period last year. whereas in FY24 sales surged by 11.39% to $5.07bn from $4.55bn in FY23.
Zoetis Inc in the last 3 months the stock has given a return of 1%, and the stock price increased to $163.5 as of Apr 02, 2025, from $162.61 as of Jan 02, 2025.
Executive Summary
• CrispIdea Forecast
– Income Statement
– Balance Sheet
– Cash Flow
– Common Size Ratio Analysis
– CrispIdea Segment Forecast
• Valuation & Historical Performance
– P/E Analysis
– CrispIdea Valuation
– Peer Comparison
– Ratio Analysis
– Economic Value-Added Analysis
– Du Pont Analysis
– CrispIdea Forecast Relative to Consensus
– Consensus Momentum
– Segment Performance
– Key Developments
– M&A Deals
• Ownership
• Stock Price Performance
• Crispidea Coverage
https://www.crispidea.com/report/zoetis-equity-report-q3-24/
